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Abstract. Practically, all chemotherapeutic agents lead to drug resistance. Clinically, it is a challenge to determine whether
resistance arises prior to, or as a result of, cancer therapy. Further, a number of different intracellular and microenvironmental
factors have been correlated with the emergence of drug resistance. With the goal of better understanding drug resistance
and its connection with the tumor microenvironment, we have developed a hybrid discrete-continuous mathematical model.
In this model, cancer cells described through a particle-spring approach respond to dynamically changing oxygen and DNA
damaging drug concentrations described through partial differential equations. We thoroughly explored the behavior of our
self-calibrated model under the following common conditions: a fixed layout of the vasculature, an identical initial configuration
of cancer cells, the same mechanism of drug action, and one mechanism of cellular response to the drug. We considered one
set of simulations in which drug resistance existed prior to the start of treatment, and another set in which drug resistance is
acquired in response to treatment. This allows us to compare how both kinds of resistance influence the spatial and temporal
dynamics of the developing tumor, and its clonal diversity. We show that both pre-existing and acquired resistance can give
rise to three biologically distinct parameter regimes: successful tumor eradication, reduced effectiveness of drug during the
course of treatment (resistance), and complete treatment failure. When a drug resistant tumor population forms from cells
that acquire resistance, we find that the spatial component of our model (the microenvironment) has a significant impact on
the transient and long-term tumor behavior. On the other hand, when a resistant tumor population forms from pre-existing
resistant cells, the microenvironment only has a minimal transient impact on treatment response. Finally, we present evidence
that the microenvironmental niches of low drug/sufficient oxygen and low drug/low oxygen play an important role in tumor
cell survival and tumor expansion. This may play role in designing new therapeutic agents or new drug combination schedules.
Key words. tumor therapy, tumor environment, hybrid model, individual cell-based model.
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1. Introduction. The effectiveness of practically all chemotherapeutic compounds that are used in
the clinical treatment of solid tumors reduces during the course of therapy [1, 2, 3, 4]. This phenomenon,
termed drug resistance, can arise due to a number of different intracellular and microenvironmental causes.
Drug resistance is not cancer-specific; it is a common cause of treatment failure in HIV infection [5], and of
antibiotic failure in bacterial communities [6]. It is often impossible to determine whether the drug resistant
cells existed prior to the start of treatment, or if they arose as a result of anti-cancer therapy. Pre-existing
(primary) drug resistance occurs when the tumor contains a subpopulation of drug resistant cells at the
initiation of treatment, and these cells become selected for during the course of therapy. Acquired resistance
involves the adaptation of a tumor cell subpopulation so that the cells gradually develop drug resistance due
to drug exposure and other factors, such as microenvironmental or metabolic conditions [7, 8].
Mechanisms of drug resistance are being studied in cell culture [9, 10]. Drug resistant cell lines are
produced by incubating cells with a particular drug, collecting the surviving cell subpopulation, and repeating
this process through several passages until the remaining subpopulation of cells no longer responds to the
treatment. While this is an effective way to generate a resistant cell population, this in vitro process does
not reveal whether the surviving cells become less responsive to chemotherapeutic treatment with each cell
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passage (acquired drug resistance), or if a small population of resistant cells was present from the beginning
and simply overgrew the other cells during the course of the experiment (pre-existing drug resistance).
Many different mechanisms can be adopted by cancer cells to resist treatment [2, 3, 4, 11, 12, 13].
These can broadly be divided into intrinsic (intracellular) causes and extrinsic (microenvironmental) causes.
As an example of intrinsic resistance, a cancer cell arrested in a quiescent state will not respond to the
killing effects of an anti-mitotic drug. Other intrinsic causes of drug resistance include enhanced DNA repair
mechanisms, increased tolerance to DNA damage, high levels of drug transporters that eliminate drug from
the cell, over-expression of drug target receptor, or accumulation of cancer stem cells. Among the extrinsic
causes of drug resistance are factors that synergistically limit cancer cell exposure to drug. These include
irregular tumor vasculature that causes chaotic drug delivery and interstitial fluid pressure that hinders drug
transport. Metabolic gradients inside tissue, such as regions of hypoxia or acidity, can also influence cell
sensitivity to a drug [7, 10, 14, 15, 16]. While these factors could be pre-existing, exposure to drug has also
been found to affect these different factors [1, 7, 17].
To narrow down the focus of this paper, we only consider a chemotherapeutic agent that chemically
reacts with and damages cell DNA. Among these are drugs routinely used in the clinic, including alkylating
agents (cisplatin, mephalan), antimetabolites (5-fluorouracil, gemcitabine), anthracyclines (doxorubicin) or
topoisomerase poisons (etoposide). DNA integrity is essential for a cell to properly function, and when
increased levels of DNA damage are detected at cell-cycle checkpoints, the cell can be arrested in its cell-
cycle to give time for DNA repair. However, in cancer cells the mechanisms of DNA damage sensing can
be loosened, and some cells are capable of ignoring cell-cycle checkpoints. We consider cancer cells with
one or more of these features to be resistant to DNA damaging drugs. These resistant cells can result in
the increased proliferation and replication of the damaged DNA. Cancer cells can also develop resistance
through increased DNA repair capabilities and increased DNA damage tolerance [12, 13, 18, 19]. Clinically,
it is generally not possible to determine which of these mechanisms result in resistance to DNA damaging
drugs, though all of these mechanisms have been observed experimentally.
Our goal is to simulate how resistance to DNA damaging drugs (administered continuously by in-
travenous injection) can emerge in individual cells and in a growing population of tumor cells. We were
interested in comparing tumor dynamics in two cases: when a small subpopulation of tumor cells is al-
ready resistant to the drug (pre-existing resistance) and when the cells can become resistant upon exposure
to the drug (acquired resistance). Theoretical analysis of the temporal components of the model, along
with numerical simulations of the full spatial model have been performed. These analyses revealed mul-
tiple biologically-distinct parameter regimes for both pre-existing and acquired resistance. In either case,
we found a parameter regime for which the effectiveness of drug is reduced during the course of treatment
(drug resistance). Focusing on the case of pre-existing resistant cells, we quantified how their location in
tissue space influences therapeutic response. When drug resistance emerges in response to treatment, we
explored which clonal populations survived treatment and how this depended on their location in tissue
space. Moreover, we present evidence that two different microenvironmental niches, low drug/low oxygen
and low drug/sufficient oxygen, have different transient and long-term impacts on cancer cell survival.
2. Mathematical Model. We have developed a hybrid discrete-continuous model of a two-dimensional
tissue slice in which a tumor grows, interacts with the microenvironment and is treated with a DNA damaging
drug. The pivotal role of the microenvironment in drug efficacy and resistance is strongly suggested through
the observation that drugs with potent in vitro activity are often significantly less effective in the clinic.
We incorporate the microenvironment by considering a small patch of tissue with imposed positions of
non-evolving blood vessels that serve as a source of both nutrients and drug. We track the features and
behaviors of individual cells; this includes their clonal evolution and their interactions with other cells and
the surrounding microenvironment. For simplicity, we do not include any stromal cells or other extracellular
components. The hybrid discrete-continuous model, described in more detail below, combines an agent-
based technique (a particle-spring model) to represent the individual tumor cells and continuous partial
differential equations to describe the kinetics of both oxygen and drug. The cellular and microenvironmental
components of our model are shown graphically in Fig.1a. A comparison of our model with other hybrid
models of tumor resistance to drugs is given in the Discussion in Section 4. In all equations below we will
use the following notation: x = (x, y) will define locations of continuous variables, such as drug and oxygen
concentrations, while (X,Y ) will denote locations of discrete objects, that is cells and vessels.
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Fig. 1. Computational model assumptions and selected simulation results. (a) Visualization of model components
at the initial stage (left), and during simulation (right): the gradient of drug (greyscale in background) is regulated by
influx from the vasculature (red circles) and by cellular uptake; the clonal origin of each individual cell is indicated by
a different symbol/color combination; hypoxic cells are surrounded by white circles. (b) Final (after 25,000 iterations)
configuration of tumor and its clonal heterogeneity in a case of no treatment. (c-d) Evolution of a tumor under
treatment, but with no resistance for two distinct initial configurations of 65 cells (Section 3.1). Both tumors will be
eradicated by treatment (not shown). (e) Evolution of a tumor when pre-existing resistant cells give rise to a resistant
tumor (reduced effectiveness of drug during the course of treatment; see Section 3.3). (f) Evolution of a tumor when
cells that acquire resistance result in the formation of a resistant tumor (Section 3.4). (g) Evolution of tumor clones
influenced by the microenvironmental niche in the case of acquired resistance (Section 3.5).
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2.1. Reaction-diffusion equation for oxygen kinetics. The change in oxygen concentration ξ at
location x = (x, y) in the tumor tissue depends on oxygen supply from the vasculature Vj at a constant rate
Sξ, its diffusion with diffusion coefficient Dξ, and cellular uptake by the nearby tumor cells Ck at rate ρξ. It
is governed by the following equation:
∂ξ(x, t)
∂t
= Dξ∆ξ(x, t)︸ ︷︷ ︸
diffusion
−min
(
ξ(x, t), ρξ
∑
k
χCk(x, t)
)
︸ ︷︷ ︸
uptake by the cells
+Sξ
∑
j
χVj (x, t)︸ ︷︷ ︸
supply
,(2.1)
where k indexes over the number of cancer cells with positions C
(X,Y )
k , and j indexes over the number of
vessels with positions V
(X,Y )
j . χ is the characteristic function defining the cell and vessel neighborhood,
whose definition depends on a fixed cell radius RC and a fixed vessel radius RV :
χCk(x, t) =
{
1 if
∣∣∣∣∣∣x− C(X,Y )k (t)∣∣∣∣∣∣ < RC
0 otherwise,
χVj (x, t) =
{
1 if
∣∣∣∣∣∣x− V (X,Y )j ∣∣∣∣∣∣ < RV
0 otherwise.
Sink-like boundary conditions (∂ξ(x, t)/∂n = −$ξ(x, t)) are imposed along all domain boundaries
x ∈ ∂Ω, where n is the inward pointing normal. The initial oxygen concentration ξ(x, t0) in the whole
model domain Ω is shown in the Appendix in Fig.9a. The method for determining the initial oxygen
distribution, oxygen boundary conditions, and oxygen uptake rates are also described in the Appendix.
2.2. Reaction-diffusion equation for drug kinetics. The change in drug concentration γ in the
tumor tissue depends on its supply from the vasculature Vj , its diffusion with diffusion coefficient Dγ , decay
with decay rate dγ , and cellular uptake by the tumor cells Ck at rate ργ . It is governed by the following
equation:
∂γ(x, t)
∂t
= Dγ∆γ(x, t)︸ ︷︷ ︸
diffusion
− dγγ(x, t)︸ ︷︷ ︸
decay
−min
(
γ(x, t), ργ
∑
k
χCk(x, t)
)
︸ ︷︷ ︸
uptake by the cells
+Sγ(t)
∑
j
χVj (x, t)︸ ︷︷ ︸
supply
,(2.2)
where Sγ(t) is a time-dependent supply function from each vessel. In this paper we assume that the drug
supply is continuous, thus we use a constant Sγ . In principle, however, this approach allows us to model
different time dependent drug administration schedules. The neighborhood function χ is defined above, and
the drug boundary conditions are defined in the same way as for oxygen. The initial conditions are defined
as follows: γ(x, t0) = 0 for x ∈ Ω \
⋃
Vk, and γ(x, t0) = Sγ at all V
(X,Y )
k . Together, these equations state
that t0 represents the start of treatment at which time drug is only found at the sites of blood vessels. The
method for determining drug boundary conditions and drug uptake rates are described in the Appendix.
2.3. Agent-based model for tumor cell dynamics. Each cell in our model is treated as a separate
entity characterized by several individually regulated properties that define cell position C(X,Y ), current cell
age Cage, cell maturation age Cmat, the level of sensed oxygen Cξ, the level of accumulated drug Cγ , the
time of cell exposure to high drug concentration Cexp, the level of accumulated DNA damage Cdam, the level
of damage that the individual cell can withstand, but upon crossing it, the cell will die (a “death threshold”)
Cdeath, and two variables used to identify cell heritage–the unique index of the host cell (IDc), and the
unique index of its mother cell (IDm), that we denote by C
(IDc,IDm). The state of the k-th cell at time t,
Ck(t), will be denoted as follows:
Ck(t) =
{
C
(X,Y )
k (t), C
age
k (t), C
mat
k , C
ξ
k(t), C
γ
k (t), C
exp
k (t), C
dam
k (t), C
death
k (t), C
(IDc,IDm)
k
}
.
The rules for updating each cell property are described below and summarized in a flowchart of cell response
to microenvironmental conditions shown in Fig. 2. Note that cells are updated in a random order at each
iteration to avoid any configurational biases.
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Fig. 2. Flowchart of cell behavior in response to microenvironmental factors. Based on signals sensed from the
microenvironment (first column) each cell can respond to oxygen levels (second column) by potentially proliferating
or becoming hypoxic, and to drug levels (third column) by either surviving, adapting, or dying. Upon cell division
(rightmost column), some cell properties are inherited, while others are sampled from the environment.
Each cell can inspect its local neighborhood and sense extracellular concentrations of both oxygen ξ and
drug γ. The quantity of oxygen taken up and used by the k-th cell (Cξk), and the amount of drug taken up
by the cell (Cγk ) are determined as follows:
Cξk(t+ ∆t) =
∑
x
ξ(x, t)︸ ︷︷ ︸
sensed & used
and Cγk (t+ ∆t) = C
γ
k (t) +
max
0,∑
x
min (γ(x, t), ργ)︸ ︷︷ ︸
uptake
− dγCγk (t)︸ ︷︷ ︸
decay

∆t,
where
{
x :
∣∣∣∣∣∣x− C(X,Y )k ∣∣∣∣∣∣ < RC} is a local cell neighborhood. The level of sensed oxygen will regulate
cell proliferative capabilities, and cells will become quiescent in a hypoxic environment (the level of sensed
oxygen falls below a predefined threshold Thrhypo).
The duration of cell exposure to the drug and its concentration will determine cell DNA damage. In
the case of acquired resistance, the duration of drug exposure also determines the cell death threshold.
While these mechanisms are assumed here, their effects are consistent with experimentally hypothesized
mechanisms of resistance, including the accumulation of mutations of drug targets or inactivation of the
drug [2]. The drug-induced DNA damage is assumed to depend on the current increase in drug consumed
by the cell (drug uptake minus drug decay) and on DNA repair (proportional to the current damage with
the rate p):
Cdamk (t+ ∆t) = C
dam
k (t) +
[
max
(
0,
∑
x
min(γ(x, t), ργ)− dγCγk (t)
)]
∆t − p Cdamk (t).(2.3)
If this accumulated damage exceeds the tolerated damage level (the death threshold Cdeathk , determined by
self-calibration in the Appendix), this cell dies.
The damage level tolerated by the cells is defined differently depending on whether we deal with pre-
existing or acquired cell resistance. In the case of pre-existing drug resistance, Cdeathk is fixed for all cellular
clones, however, it is set up to be relatively higher for the resistant clones. For simplicity, we assume that it is a
multiplier of the value for sensitive clones. Thus Cdeathk =Thrdeath for sensitive cells and C
death
k =Thrmulti×
Thrdeath for resistant cells. In the case of acquired cell resistance, the C
death
k may increase in each cell
independently (with the increase step ∆death) if the prolonged drug exposure criterion is met:
Cdeathk (t+ ∆t) =
{
Cdeathk (t) + ∆death if C
exp
k (t) > texp
Cdeathk (t) otherwise
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where texp is the prolonged drug exposure threshold that determines whether a cell’s death threshold in-
creases. Note that Cexpk is defined by introducing cell short-term memory to count how long the cell has
been exposed to a high drug concentration γexp:
Cexpk (t+ ∆t) =
{
Cexpk (t) + ∆t if C
γ
k (t) > γexp
0 otherwise.
Cell current age is updated as follows: Cagek (t+∆t)=C
age
k (t)+∆t. We assume that when the cell reaches
its maturation age, Cmatk , it is ready to divide unless it is surrounded by other cells (the overcrowding
condition), in which case cell proliferation is suppressed until space becomes available. Upon division of the
k-th cell, Ck(t), two daughter cells are created instantaneously (Ck1(t) and Ck2(t)). One daughter cell takes
the coordinates of the mother cell, whereas the second daughter cell is placed randomly near the mother cell;
that is:
C
(X,Y )
k1 (t) = C
(X,Y )
k (t) and C
(X,Y )
k2 (t) = C
(X,Y )
k (t) +RC (cos(θ), sin(θ)) ,
where θ is a random angle. The current age of each daughter cell is initialized to zero, Cagek1 (t)=C
age
k2 (t)=0,
however the cell maturation age is inherited from its mother cell with a small noise term: Cmatk1 , C
mat
k2 =C
mat
k ±
ω, with ω ∈ [0, Cmatk /20]. Moreover, both daughter cells inherit from their mother the level of DNA damage
Cdamk1 (t)=C
dam
k2 (t)=C
dam
k (t), the death threshold C
death
k1 (t)=C
death
k2 (t)=C
death
k (t), and the drug exposure time
Cexpk1 (t)=C
exp
k2 (t)=C
exp
k (t). However, the level of accumulated drug is divided equally between the two daugh-
ter cells Cγk1(t)=C
γ
k2(t)=0.5×Cγk (t), and the levels of sensed oxygen Cξk1(t) and Cξk2(t) are determined inde-
pendently for each cell based on oxygen contents in the cell vicinity. Furthermore, the unique index of each
daughter cell consists of the newly assigned index and the inherited mother index, i.e., C
(IDc,IDm)
k1 =(k1, C
IDc
k )
and C
(IDc,IDm)
k2 =(k2, C
IDc
k ). This is summarized in the “cell inheritance” column of Fig. 2. Initial proper-
ties of the k-th tumor cells are: Ck(t0) =
{
(Xk, Yk), 0,Mk,
∑
x
ξ(x, t0), 0, 0, 0, Tk, (k, 0)
}
, where Mk is drawn
from a uniform distribution [0.5 × Age, 1.5 × Age], and Age is the average maturation age. Tk=Thrdeath
for all cells in the acquired resistance case, and for all sensitive cells in the pre-existing resistance case.
Tk=Thrmulti × Thrdeath for all resistance cells in the pre-existing resistance case. This means that all cells
start at their pre-defined position (Xk, Yk), at age zero with whatever amount of oxygen they sense from
the local microenvironment. There is no drug in any of the cells initially, and cells have been exposed to
the drug for no time. Further, cells have not accumulated any damage and all cells have a pre-defined death
threshold. Each initial cell has an unknown mother, thus its unique index is (k, 0), and the first component
is passed along to its daughters as a mother cell index.
2.4. Equations of cell mechanics. The equations of cell mechanics are based on the previously
published model by Meineke et al. [20], in which cells are represented by the coordinates of its nucleus
C(X,Y )(t) and a fixed cell radius RC . Thus, each cell is assumed to have a default volume that is maintained
during its lifetime, and the neighboring cells push each other away by exerting repulsive forces if they come
into contact (i.e., if the distance between the cells is less than the cell diameter 2RC). Therefore, the change
in cell position depends on interactions with other cells in the neighborhood. Two repulsive (linear, Hookean)
forces fi,j and −fi,j will be applied to cells C(X,Y )i (t) and C(X,Y )j (t), respectively, to move these two cells
apart and preserve cell volume exclusivity. To simplify notation in the equations below, we let Xi=C
(X,Y )
i (t).
Then,
fi,j =
{
F (2RC − ‖Xi −Xj‖) Xi−Xj‖Xi−Xj‖ if ‖Xi −Xj‖ < 2RC
0 otherwise,
where F is the constant spring stiffness, and the spring resting length is equal to cell diameter. If the cell Xi
is in a neighborhood of more than one cell (say, Xj1 , . . . ,XjM ), the total force Fi acting on Xi is the sum of
all repulsive forces fi,j1 , . . . , fi,jM coming from the springs between all neighboring cells connected to Xi:
Fi = F(2RC − ‖Xi −Xj1‖)
Xi −Xj1
‖Xi −Xj1‖︸ ︷︷ ︸
fi,j1
+ . . .+ F (2RC − ‖Xi −XjM ‖)
Xi −XjM
‖Xi −XjM ‖︸ ︷︷ ︸
fi,jM
.
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Cell dynamics are governed by the Newtonian equations of motion where the connecting springs are
overdamped (system returns to equilibrium without oscillations). Damping force is related linearly to velocity
with a damping coefficient ν, and thus the force and cell relocation equations are given by:
Fi = −ν dXi
dt
and Xi(t+ ∆t) = Xi(t)− 1
ν
∆tFi.
When a dividing cell gives rise to two daughter cells, the repulsive forces between daughter cells are
activated since they are placed at the distance smaller than cell diameter. Further, this may also result in
daughter cell placement near other tumor cells. Therefore multiple repulsive forces will be applied until the
cells are pushed away and the whole tumor cluster reaches an equilibrium configuration. The introduction of
repulsive cell-cell interactions also allows for monitoring the number of neighboring cells, which determines
whether the cells are overcrowded. This, in turn, influences subsequent tumor growth. It is of note that some
cells get pushed out of the domain after the cluster reaches an equilibrium configuration. Only cells that
remain inside the domain are considered in our analysis. All model parameters that define cell mechanics
are summarized in Table 1.
Table 1
Physical and computational parameters of cell mechanics.
cellular parameters: numerical parameters:
Cell radius RC=5 µm Domain size [−75, 75]× [−75, 75] µm
Spring stiffness F=1 mg/s2 Mesh width hb=2µm
Mass viscosity ν=15 mg/s Time step ∆t=0.5min
Overcrowding Neighbors=14 cells
Maturation age Age=360min ± noise∈[0,Age/20]
2.5. Numerical implementation of model equations. A finite difference scheme is used to ap-
proximate the solution of the partial differential equations for oxygen and drug. Space is discretized into
a square grid, with spacing between grid points of hb. Time is also discretized with a time step ∆t. The
numerical values of these parameters are given in Table 1. The solution to the partial differential equation is
then approximated using a forward-difference approximation (in time) on a square grid (centered in space),
using sink-like boundary conditions as detailed in Section 2.1. At each time step, the initial conditions for
approximating γ(x, t+ ∆t) and ξ(x, t+ ∆t) are the values of γ(x, t) and ξ(x, t), respectively. We prescribed
the initial values, γ(x, t0) and ξ(x, t0), as detailed above and in Table 2, whereas the values of γ and ξ at all
t > 0 are determined by finite difference approximation.
Table 2
Non-dimensionalized parameters of oxygen and drug kinetics based on calibration presented in Appendix.
metabolite kinetics (normalized values): drug resistance (normalized values):
oxygen: drug: pre-existing: acquired:
Supply rate Sξ=1 Sγ=1 Death thresh. incr. ∆death=0 ∆death varies
Diffusion coefficient Dξ=0.5 Dγ=0.5 Death thresh. mult. Thrmulti=5 Thrmulti=1
Decay rate none dγ=1×10−4 Drug exposure level N/A γexp=0.01
Boundary outflux rate $=0.45 $=0.45 Drug exposure time N/A texp=5∆t
Cellular uptake ρξ=5Sξ×10−5 ργ=Sγ×10−4 DNA repair p varies p=1.5×10−4
Threshold value Thrhypo=0.05 Thrdeath=0.5
Cell-drug and cell-oxygen interactions are also modeled at the same discretized time points for which
we numerically approximate the solution to the partial differential equation. In particular, at each discrete
time point, any discrete grid point within a fixed distance RC from the center of a cancer cell can uptake
drug for that cancer cell at a uptake rate ργ , provided this amount of drug is available. If there is not enough
drug at the site to take up ργ units, all the drug available at the site is taken up by the grid point for the
associated cell. Finally, we also assume that drug found inside the cell decays at the same rate as it does
in the environment. In a similar way oxygen is taken from the environment at the rate ρξ and immediately
used by the cells. All non-dimensionalized parameter values used in our model are summarized in Table 2
(see Appendix for parameter self-calibration).
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3. Results. An analysis of our calibrated model is undertaken here. To facilitate comparisons between
simulations so that only the impact of resistance type (none, pre-existing, acquired) is assessed, all simulations
(with one noted exception) use the same initial condition for the configuration of 65 tumor cells (each
individually represented by a unique shape/color combination) and blood vessels, shown in Fig.1a, left.
Further, all simulations are run using a fixed seed for the random number generator. We first explain tumor
dynamics upon treatment with a continuously-administered DNA damaging drug when neither mode of
resistance is incorporated. Following this, we make some analytical predictions on tumor behavior, under
the simplifying assumption that long-term behavior is not influenced by the spatial features of the model.
In the case of pre-existing resistance, the theoretical analysis is supported by numerical simulations. In
the case of acquired resistance, numerical simulations are also conducted, although the connection to the
theoretical analysis is less straightforward. We conclude by studying the impact that spatial location and
microenvironmental niche have on tumor response to treatment.
3.1. Analysis of treatment outcome with no tumor resistance. Here, we consider the case when
no form of anti-cancer drug resistance can develop. This means that all cells initially have the same tolerance
to drug damage (parameter Thrmulti is set to 1), and this tolerance will not increase during the course of
treatment (parameter ∆death set to 0). The model has been calibrated (see Appendix) so that in this case
the drug is successful and all tumor cells will be eliminated in a relatively short time (after several cell
cycles). Moreover, the drug should eradicate the tumor regardless of initial cell configuration. Thus here we
discuss two cases that differ only by the initial locations of tumor cells. The first case, shown in Fig.1c(i),
is comprised of a dispersed cluster of cells initially located at varying distances from the vasculature. The
second case is shown in Fig.1d(i) and contains cells located within the low drug niche (see Section 3.5),
relatively far from all vessels. All other model parameters are identical in both cases, including the death
threshold (Thrdeath=0.5) and DNA repair rate (p=1.5×10−4), as listed in Table 2.
Fig. 3. No-resistance case. Comparison of cell evolution curves (a,c) and cell damage curves (b,d) for two distinct
initial conditions shown in Fig.1c(i) and Fig.1d(i). The numbers in (a) and (c) correspond to color panels in Fig.1c
and Fig.1d, respectively. The curves in (b) and (d) show an average damage level of all cells with the standard
deviation represented by vertical lines, and an average death threshold of all cancer cells, which here is constant.
In both cases the qualitative behavior of the whole cell population is similar, as can be seen by compar-
ing cell evolution curves in Fig.3a and Fig.3c. Initially, the cells do not encounter enough drug to die off,
thus allowing them to increase the cell population by 4-5 fold (Fig.3a(ii) and Fig.3c(ii)) and overtake a large
portion of the domain. The corresponding cell configurations are shown in Fig.1c(ii) and Fig.1d(ii), respec-
tively. During this time the majority of cells steadily accumulate DNA damage (Fig.3b,d) and subsequently
die when the damage level exceeds the death threshold (Fig.3a(iii) and Fig.3c(iii)). The exception to this
is a small cell cluster located in the low drug niche (Fig.1c(iii) and Fig.1d(iii)). These small subpopula-
tions are able to briefly recover and temporarily increase tumor size (Fig.3a(iv), Fig.1c(iv) and Fig.3c(iv),
Fig.1d(iv)), although both tumors eventually die out. Tumor eradication in both cases took place within
several cell cycles, although the tumor initiated within the low drug niche survived slightly longer than the
dispersed configuration: 9 cell cycles versus 11 cell cycles, with an average cell cycle counting 720 itera-
tions. The main difference between these two cases is in the number of persistent clones (one in Fig.1c(iv)
and several in Fig.1d(iv)), which suggests that certain cell clones may be selected by microenvironmental
conditions and thus survive longer. This may have implications for the development of tumor resistance
since subpopulations that confer a certain advantage within the tissue may give rise to distinct resistance
capabilities or indeed to a resistant phenotype.
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3.2. Theoretical analysis of the parameter space with resistance. In this section, we theoret-
ically analyze the damage incurred in cancer cells during treatment. We are interested in predicting the
parameter regimes for which the damage accumulated by cancer cells Cdam exceeds their death threshold
Cdeath, as this is the situation that results in cancer cell death.
To facilitate our analysis, we first assume that each cell incurs the same amount of DNA damage. In
other words, at any fixed time t, all cells will have the same level of DNA damage. In the equations below,
we let x(t) = Cdamk (t) be the notation used to represent this spatially-constant damage level. Further, let
η(t) > 0 represent the new amount of damage incurred in each cell at time t, and define 0 ≤ p ≤ 1 to be the
constant fraction of DNA damage repaired. Therefore, for any small h, and any t > 0 we have:
x(t) = x(t− h) +
∫ t
t−h
η(s) ds−
∫ t
t−h
px(s) ds.
Using the Fundamental Theorem of Calculus in the limit as h→ 0, this statement reduces to
x˙ = η(t)− px(t).(3.1)
Assuming no damage at t=0, i.e., x(0)=0, the following describes the explicit solution of Equation (3.1)
x(t) =
(∫ t
0
η(s)epsds
)
e−pt.(3.2)
In what follows, we further assume that η(t) = η is constant, so that the amount of new damage induced
by the drug in each cell is constant. This is not necessarily the case in our spatial model, since the damage
incurred by a cancer cell depends on the amount of drug that reaches the cancer cell, and that depends on
the location of the cell in tissue space, and potentially on how long the drug has been administered. However,
since the drug influx from the vessels is also constant, the amount of damage in each time point is bounded
from above. We call this value η.
For p 6= 0, Equation (3.2) becomes:
x(t) =
η
p
(
1− e−pt) .(3.3)
For p = 0, meaning there is no DNA damage repair, Equation (3.2) becomes:
x(t) = η t.(3.4)
3.2.1. Pre-existing case. In the pre-existing case, we start with two clones with a death threshold
that is larger than the rest of the cells. We call this threshold β1=Thrmulti × Thrdeath. Since these clones
can tolerate more DNA damage than the others, they are called resistant. The rest of the clones are called
sensitive and their death threshold is β2=Thrdeath. Moreover, ∆death = 0 since no drug resistance can be
acquired during the course of treatment. Therefore, Cdeath(t) = β1 for resistant clones, and C
death(t) = β2 for
sensitive clones, with β2 < β1. In the following proposition we provide conditions for cancer cell eradication
(x(t) > Cdeath(t)) and for cancer cell survival (x(t) < Cdeath(t)).
Proposition 3.1.
1. For 0 ≤ p < η
β1
, both resistant and sensitive clones die, i.e., there exists T > 0 such that for any
t > T , x(t) > β1 > β2.
2. For
η
β1
< p <
η
β2
, resistant clones survive but sensitive clones die, i.e., there exists T > 0 such that
x(t) > β2 for any t > T but x(t) < β1 for any t.
3. For p >
η
β2
, all clones survive, i.e., x(t) < β2 < β1 for any t.
Proof. For i = 1, 2, let Fi(t) := x(t)− βi. We consider the following two cases:
• p = 0. In this case, using Equation (3.4), x(t) = ηt. Hence, when t > β1η , ηt = x(t) > β1 > β2.
• p > 0. In this case, using Equation (3.3),
Fi(t) =
η
p
− η
p
e−pt − βi.
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Note that F (0) = −β < 0 and F ′(t) = ηe−pt > 0. Therefore, if lim
t→∞Fi(t) =
η
p
− βi > 0, it follows
by Intermediate Value Theorem that Fi has a unique positive root T and, furthermore, Fi(t) > 0
for t > T . If on the other hand lim
t→∞Fi(t) =
η
p
− βi < 0, then Fi(t) < 0 for all t ≥ 0.
1. For p <
η
β1
<
η
β2
, we have:
lim
t→∞Fi(t) =
η
p
− βi > 0, for i = 1, 2.
Therefore, there exists T > 0 such that x(t) > β1 > β2 for all t > T .
2. For
η
β1
< p <
η
β2
, we have:
lim
t→∞F2(t) =
η
p
− β2 > 0, lim
t→∞F1(t) =
η
p
− β1 < 0.
Therefore, there exists T > 0 such that for t > T , x(t) > β2, but for all t ≥ 0, x(t) < β1.
3. For p >
η
β2
, we have:
lim
t→∞Fi(t) =
η
p
− βi < 0, for i = 1, 2.
Therefore, x(t) < β2 < β1, for all t ≥ 0.
When 0 ≤ p ≤ ηβ , our analysis predicts tumor eradication by a continuously-administered DNA dam-
aging drug. Simulations of our model for the calibrated parameter values reveal that η ≤ ηmax = 3× 10−4.
Since we have assumed a constant value of η for all cells for all time, we will use η = 3 × 10−4 to make
numerical predictions from our theoretical results. Further, we have fixed β1 = 2.5 which means that part
1 of Proposition 3.1 predicts that if p < 1.2 × 10−4, complete tumor eradication is expected as long as
treatment is administered for a sufficiently long period of time.
When ηβ1 < p <
η
β2
, which numerically corresponds to DNA damage repair in the range (1.2× 10−4, 6×
10−4), part 2 of Proposition 3.1 predicts that all sensitive clones should be eradicated, although resistant
clones should persist. Finally, when p > 6× 10−4, all clones are predicted to survive the treatment protocol.
In Section 3.3, we will demonstrate that these theoretical predictions are consistent with our numerical
simulations of the full spatial model, when considering the long-term dynamics. The theoretical analysis
does not reveal information about the transient dynamics of the model.
3.2.2. Acquired case. We also performed a theoretical analysis of the damage level and death thresh-
old in the case of acquired resistance. Just as with the pre-existing analysis, we assumed that all cancer cells
incur constant levels of damage for all time points during treatment (η=3×10−4). However, damage incurred
by a cell actually depends on the amount of drug the cell receives, and this depends on the location of the
cell in tissue space. While this neglect of the spatial component gave informative predictions in the case
of pre-existing resistance, the predictions end up being less informative in the case of acquired resistance.
For this reason, the theoretical analysis of acquired resistance will be presented in Section 3.5.2, where we
discuss the importance of spatial location and microenvironmental niche on tumor survival.
3.3. Simulations in the case of pre-existing resistance. In the case of pre-existing resistance, a
subpopulation of tumor cells that are resistant to the DNA damaging drug are present at the initiation of
treatment. As detailed in Section 3.2, pre-existing resistance is simulated through the Thrmulti parameter.
While sensitive clones have a death threshold Thrdeath=0.5, the threshold of resistant cells is increased by a
multiple of Thrmulti > 1. We randomly choose two cells (approximately 3% of the initial tumor population)
to have pre-existing resistance. Since the location and proximity of a resistant cell to a blood vessel could
have a major impact on whether the cell will live or die, here we only consider the two resistant cells to be
at an intermediate distance from the vessels. In Section 3.5.1, we will explore the impact of the location of
the resistant cells.
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In the pre-existing resistance simulations, we vary p, the constant fraction of DNA damage repaired.
Although Thrmulti is the more obvious pre-existing resistance parameter, it is the relationship between p
and Thrmulti that determines tumor response to the DNA damaging drug. The time scales in the model are
easier to control (and this facilitates comparison between different cases) when we fix Thrmulti and allow p
to vary. For all pre-existing analysis and simulations, we fix Thrmulti = 5.
Fig. 4. Pre-existing resistance case. A comparison of tumor evolution curves (a-c) and tumor damage curves
(d-f) in three distinct cases: tumor eradication when p = 0 (a,d), tumor resistance when p = 1.5 × 10−4 (b,e), and
treatment failure when p = 10−2 (c,f). The curves in (d-f) show an average damage level and an average death
threshold level of all cells with the standard deviation represented by vertical lines.
3.3.1. Successful treatment. Consistent with our theoretical analysis, continuous administration of a
DNA damaging drug results in eventual tumor eradication when 0 ≤ p ≤1.2×10−4. The case of p=0 is shown
in Fig. 4a,d. Within this parameter regime, tumor behavior is qualitatively similar to the case of no drug
resistance (Fig.3a,b). Both simulations exhibit a transient period for which cancer cells accumulate, but do
not yet respond to, the drug. During this time period, a clonally heterogeneous tumor begins to grow in tissue
space while, simultaneously, the average cellular DNA damage level is increasing. Since the average death
threshold in the cancer cell population is low (the majority of cells starts with a small death threshold), the
sensitive cells start dying and the tumor population shrinks in size (Fig.4a,d). This leads to selection of the
resistant cancer cells, as demonstrated by the rapid increase in the average death threshold in Fig.4d. This
tumor, eventually composed entirely of resistant cells (saturation in the average death threshold), undergoes
a significant period of regrowth before the entire population experiences a rapid increase in DNA damage
levels and is eradicated by the drug. Therefore the model reveals that a DNA damaging drug can eliminate
a tumor with a subpopulation of resistant cells that existed prior to the onset of treatment.
3.3.2. Emergence of a drug resistant tumor. Our theoretical analysis predicts that when 1.2 ×
10−4 < p < 6 × 10−4, resistant cells will survive treatment while sensitive cells will be eradicated. The
dynamics of this process, however, can only be revealed through numerical simulations. We find that in this
parameter regime, the effectiveness of the DNA damaging drug is reduced during the course of treatment
(Fig.4b where p = 1.5 × 10−4). This is what we consider to be a drug resistant tumor, and what is often
observed clinically when treating patients with a chemotherapeutic agent.
In this parameter regime, the early tumor dynamics are comparable to the successful treatment case:
after an initial period of time during which cancer cells build up drug levels, there is a transient period
of tumor shrinkage (Fig.4b). Fig.1e(ii) reveals that only three clones are selected for during this period
of time: the two resistant clones (red and blue), and the one sensitive clone located in a low-drug niche
(yellow). These surviving clones begin to repopulate tissue space. Unlike in the successful treatment case,
the drug cannot eliminate the resistant cells, though it can eliminate the sensitive cell in the low drug niche.
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This is seen in Fig.4e where the average death threshold of the surviving cells has stabilized at a value of
2.5, whereas the average damage level is actually decreasing from a maximum value of approximately 1.25.
Therefore the damage levels cannot surpass the death threshold of the cells, and at the end of the simulation
period, we are left with a resistant tumor composed entirely of resistant cells.
3.3.3. Complete treatment failure. Consistent with theoretical predictions, when p > 6 × 10−4,
all clones survive treatment with a DNA damaging drug. Simulations further reveal that the tumor grows
monotonically in this parameter regime, meaning the drug fails to exhibit any anti-tumor activity (Fig.4c
where p = 10−2). Treatment failure occurs because the level of DNA damage repair is so large it prevents the
damage level of each cancer cell, whether resistant or sensitive, from exceeding its death threshold (Fig.4f).
In this parameter regime, a clonally diverse tumor overtakes space, comparable to what is observed when
the tumor grows with no treatment (Fig.1b).
3.4. Computational analysis of the parameter space in the case of acquired resistance. In
the case of acquired resistance, a subpopulation of tumor cells evolve a resistant phenotype due to selective
pressures imposed by the drug, microenvironment, or other factors. In other words, no drug resistant cells
are found in the tumor when treatment is initiated.
As detailed in Section 2, acquired resistance is simulated in an individual cell in response to prolonged
drug exposure. If a cell meets the prolonged drug-exposure criterion, then its death threshold Cdeathk gets
incremented by ∆death. A cell whose death threshold gets increased in this way can tolerate greater levels
of DNA damage, as cell death is triggered when the damage level of a cell Cdamk exceeds its death threshold.
We computationally analyzed the model fixing all parameters as detailed in Table 2. This includes
fixing the DNA repair constant (the parameter varied in the pre-existing resistance case) to p = 1.5× 10−4.
This p was chosen because it gave rise to a drug resistant tumor in the case of pre-existing resistance. In
order to isolate the impact of acquired drug resistance, the only parameter that was varied here is ∆death.
Computational analysis of the model reveals four distinct parameter regimes, depending on the value of
∆death: 1) successful treatment; 2) almost successful treatment; 3) eventual emergence of a drug resistance
tumor; 4) complete treatment failure.
Fig. 5. Acquired resistance case. A comparison of tumor evolution curves (a-d) and tumor damage curves (e-h)
in four cases: tumor eradication when ∆death=10
−5 (a,e), almost successful treatment when ∆death=3.5×10−5 (b,f),
tumor resistance when ∆death=5.9×10−5 (c,g), and treatment failure when ∆death=10−4 (d,h). The curves in (e-h)
show an average damage level and an average death threshold with the standard deviation represented by vertical lines.
3.4.1. Successful treatment. As in the case of pre-existing resistance, there is a parameter regime
for which treatment is successful in spite of any resistance acquired to the DNA damaging drug. Simulations
reveal that the tumor eradication parameter regime is: 0 ≤ ∆death < 3× 10−5. The case of ∆death = 10−5 is
illustrated in Fig.5a,e. Within this parameter regime, the tumor is not monotonically decreasing in size, as
observed in the no resistance case and in the successful treatment of a tumor with pre-existing resistant cells
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case (Fig.3a). There is a transient period of time (approximately five cell cycles in length) during which the
cancer cells accumulate drug but do not respond to the drug.
Once drug levels have caused enough DNA damage, a transient period of tumor shrinkage occurs.
The cancer cells that are eliminated during this period are the ones with adequate access to the drug.
This period of tumor shrinkage is always followed by a period of regrowth, during which cells in the low-
drug microenvironmental niche temporarily repopulate tissue space. However, this period of drug-induced
resistance is transient, and the tumor is eventually eradicated by the DNA damaging drug.
Therefore, the model reveals that a cancer can be successfully eliminated by a DNA damaging drug
that induces resistance after prolonged exposure. In other words, just because the cells have the ability to
acquire resistance to the drug, this does not mean a drug resistant tumor will develop.
3.4.2. Almost successful treatment. Simulations also revealed a parameter regime that was not
found in the pre-existing resistance case. When ∆death satisfies 3×10−5 ≤ ∆death < 4×10−5, the drug shrinks
the tumor to a very small number of cancer cells (Fig.5b where ∆death = 3.5×10−5). The reason the tumor
is not fully eradicated by treatment is because the surviving cells are all stuck in hypoxic microenvironmental
niches (not shown). Evidence that the few cancer cells found in the hypoxic niche will survive treatment
is seen in Fig.5f. The average death threshold of the surviving cells is increasing (cells are continuing to
acquire resistance) while the average damage level is decreasing (cells are repairing more damage than they
are accumulating).
Other than the persistence of a small number of hypoxic cancer cells, the dynamics observed in this
parameter regime are qualitatively the same as the successful treatment parameter regime. Further, since the
vasculature is not evolving in our model and since the cells are not actively motile, there is no mechanism for
the surviving hypoxic cells to re-enter the cell cycle and trigger tumor expansion. Therefore, this is another
parameter regime for which cells have the ability to acquire resistance to a DNA damaging drug, but a drug
resistant tumor does not develop.
3.4.3. Emergence of a drug resistant tumor. Computational analysis revealed that for 4×10−5 ≤
∆death < 7 × 10−5, the effectiveness of the DNA damaging drug is reduced over time. Just as in the
pre-existing case, this is what we consider a drug resistant tumor.
The precise trajectory of the tumor, and its clonal composition, depends sensitively on the selected
value of ∆death within this parameter range. For instance, when ∆death = 4.5×10−5, there are two transient
periods of tumor shrinkage before a clonally homogeneous tumor overtakes tissue space (Fig.1g). The one
surviving tumor clone is initially located in low-drug niche in tissue space, and eventually emerges from these
lower-drug regions to overtake space. This will be discussed further in Section 3.5.2.
On the other hand, when ∆death = 5.9 × 10−5, there is only one transient period of tumor shrinkage
(Fig.5c) preceding the formation of a drug resistant tumor. The spatial dynamics and clonal history of the
tumor are interesting to track in this case. The growth curve in Fig.5c shows a local maximum around 4000
iterations. At this point a clonally heterogeneous tumor has practically overtaken tissue space (Fig.1f(i)).
However, Fig.5g shows that around this local maximum, the average damage level of the cancer cells catches
up to the average death threshold, and this leads to a period of time during which the drug effectively reduces
the tumor size. At the local minimum, some clonal diversity has been lost. Most cells are found in either
hypoxic or low-drug niches, although there are some cells found in normoxic zones where drug is readily
accessible (Fig.1f(ii)).
After the tumor escapes its local minimum, the average death level of the surviving cancer cells diverges
from the average damage level, and a more clonally heterogeneous tumor overtakes tissue space (Fig.1f(iii)).
It is interesting to compare this to the case of pre-existing resistance. The number of clones that survive
in pre-existing drug resistant tumors is precisely the number of resistant clones present in the tumor before
any treatment. In the acquired case, the number of clones in the resistant tumor sensitively depends on the
value of ∆death within the drug resistant parameter range. We observed that when ∆death = 4.5×10−5 only
one clone survives, which is less clonally diverse than our pre-existing resistance case. ∆death = 5.9 × 10−5
corresponds to nine different clones surviving treatment, which is more clonally diverse than the pre-existing
case (Fig.1e(iii)).
3.4.4. Complete treatment failure. Computational analysis reveals that when ∆death ≥ 7 × 10−5,
the DNA damaging drug fails to cause any reduction in the number of cancer cells. Treatment failure occurs
because the drug induces resistance in the cancer cells quicker than it damages the DNA. In this parameter
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regime, a clonally diverse tumor overtakes tissue space, and the tumor never shrinks in response to treatment
(Fig.5d,h where ∆death = 10
−4). The clonal composition of the tumor after 25,000 iterations of growth is
comparable to the composition of a tumor grown with no treatment (Fig.1b).
3.5. Impact of spatial location and microenvironmental niches on tumor survival. Microen-
vironmental conditions such as the position of vasculature can influence tumor growth and heterogeneity.
Cells require oxygen to survive and replicate, but proximity to blood vessels also means higher exposure to
drug. Regions of the tissue landscape where blood vessels are far enough away to minimize drug exposure
while still close enough to maintain adequate oxygen levels will facilitate tumor growth. This can already be
seen in the non-resistant tumor cases (Section 3.1). While both discussed tumors died out, it took longer to
eradicate the tumor initiated near the microenvironmental niche of low drug concentration. Moreover, this
niche also gave rise to a subpopulation of cells able to recover from drug insult, although only temporarily.
Our tissue landscape contains a cluster of three blood vessels and an additional solitary blood vessel
near the boundary of the tissue space (Fig.6a). This leads to a low-drug/normoxic niche near the center of
the tissue sample, and a low-drug/hypoxic region at much of the boundary of the region.
Fig. 6. Evolution of acquired resistance as an effect of microenvironmental niches of low drug and hypoxia. (a)
Tissue landscape with two microenvironmetal niches: a low-drug/hypoxic (H & low D) and low-drug/normoxic (low
D). The grey-scale contours indicate drug distribution. The black circles indicate four vessels. (b) A cell population
evolution curve with numbers corresponding to color panels in Fig.1g. (c) An average damage level and an average
death threshold of all cells with the standard deviation represented by vertical lines.
3.5.1. Pre-existing resistance: impact of cell location. As discussed in Section 3.3, the initial
condition for our pre-existing resistance simulations was a large population of sensitive cells with a subpop-
ulation of two resistant cells (approximately 3% of the population). To study how the microenvironment
influences the survival and heterogeneity of tumors under this condition, we varied which two cells were
chosen to be resistant. In particular, we tested three different configurations: 1) resistant cells chosen to be
the two cells closest to blood vessels; 2) resistant cells chosen at an intermediate distance from the blood
vessels; and 3) resistant cells chosen to be the two cells furthest from the vessels.
Consistent with our theoretical analysis of pre-existing resistance in Section 3.2, we found that long-term
tumor behavior was controlled by the relationship between the value of p (the fraction of damage repaired)
and the pre-exiting resistance parameter Thrmulti. It was only minimally influenced in the short term by
the positioning of the two resistant cells in space. Our simulations showed that the same three parameter
regimes discussed in Section 3.3 led to tumor eradication, a transient period of tumor shrinkage followed by
treatment failure, and monotonic tumor growth respectively, regardless of the proximity of the two resistant
cells to the vasculature (Fig.7).
We conclude that in the case of pre-existing resistance, just the presence of the resistant cells combined
with the DNA repair parameter value drives the overall tumor dynamics. The position of resistant cells, on
the other hand, only serves to adjust the time scale of tumor growth or death. This suggests that pre-existing
resistance is a stronger promoter of tumor growth than is a preferential microenvironment.
3.5.2. Acquired resistance: impact of microenvironmental niche. To illustrate the important
role of the spatial component of the model in the case of acquired resistance, we first turn to a theoretical
analysis that neglects the spatial component. Consider α = ∆death 6= 0, which corresponds to cells having a
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Fig. 7. Evolution of tumor size for different choices of resistant cell location and values of DNA damage repair p.
For each plot shown, the x-axis is the number of iterations (in units of 103) and the y-axis is the number of cells.
death threshold of approximately Cdeath(t) = αt+ β, where β = Thrdeath = 0.5 is fixed. As in Section 3.2,
let η > 0 represent the new amount of damage incurred in each cell at time t (assumed to be constant),
and let p be the constant fraction of damage repaired. In the following proposition we provide a condition
that guarantees that if we ignore the spatial component of the model, the cancer should be eradicated by
treatment (that is, x(t) = Cdamk (t) > C
death(t)).
Proposition 3.2. If α < η and 0 < p <
η
β
, then there exists α∗ < α, T1(α∗) and T2(α∗) such that for
all T1(α
∗) < t < T2(α∗), x(t) > αt+ β. (All cells die.)
Proof.
Let F (t) := x(t)− αt− β. Using Equation (3.3),
F (t) =
η
p
− β − αt− η
p
e−pt.
Note that F (0) = −β < 0 and F ′(t) = ηe−pt − α. Since α < η,
F ′(t) =
 ≥ 0 t ≤ t
∗
0 t = t∗
≤ 0 t ≥ t∗
where t∗ = −1
p
ln
α
η
. Therefore, the graph of F is one of the three graphs shown in Fig. 8, depending on
the size of α. Note that if for some α < η, F (t∗) > 0, then there exists an interval (T1, T2), such that for
t ∈ (T1, T2), F (t) > 0, i.e., x(t) > αt+ β. Therefore, we will look for those α’s, α < η, such that F (t∗) > 0.
Let F (t∗) = G(α) =:
η
p
− β − α
p
(
1− ln α
η
)
. Observe that:
• lim
α→0+
G(α) =
η
p
− β =
{
> 0 p < η/β
< 0 p > η/β
.
• lim
α→η−
G(α) = −β < 0.
• on (0, η), G′(α) = 1
p
ln
α
η
< 0.
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Fig. 8. All possible graphs for function F , depending on the value of α.
Therefore, if p <
η
β
, by Intermediate Value Theorem, there exists 0 < α∗ < η such that G(α∗) = 0, and
G(α) > 0 for α < α∗, and G(α) < 0 for α > α∗. Hence, if p <
η
β
, and α < α∗, then F (t∗) > 0, and there
exist T1, T2, depending on α
∗, such that for T1 < t < T2, F (t) = x(t)− αt− β > 0.
Proposition 3.2 says that if p <
η
0.5
< 6 × 10−4 and if α < η < 3 × 10−4 (both upper bounds fixed
using parameters in our model), all cancer cells should be eradicated by the DNA damaging drug. In our
numerical simulations, we consider p = 1.5 × 10−4, so p satisfies this constraint. Further, the maximum
value of α we consider is 10−4, which also satisfies the constraint imposed by this proposition. Therefore
the proposition implies that for all the simulations presented in Section 3.4, treatment should successfully
eradicate all tumor cells. Yet, this is only consistent with two of the four numerical simulations presented.
The other two cases correspond to a drug resistant tumor and complete treatment failure.
This discrepancy can be explained by the one assumption made during the theoretical analysis: we
assumed that all cancer cells incur constant levels of damage at each time point during treatment (η).
However, the damage incurred by a cell is actually a function of both space and time. So, if we consider the
statement from the proposition that p < η/0.5 guarantees tumor eradication, and if we insert the fact that
we use p = 1.5× 10−4 in our simulations, this implies that η > 7.5× 10−5 is needed to guarantee the tumor
eradication.
However, cells located at sufficient distances from the vasculature accumulate less drug than cells closer
to the vasculature, and therefore incur less damage. For these cells, the condition η > 7.5 × 10−5 is not
necessarily met, as η will be small when drug levels are low. This phenomenon can result in the theoretical
prediction (which ignores the spatial component) failing to match up with the numerical simulations (which
include the spatial component). Thus, space is clearly playing a very important role in treatment response
when resistance to a DNA damaging drug is acquired during the course of treatment.
To further understand the importance of the microenvironmental niche in the case of acquired resistance,
we tracked the clonal evolution of the tumor. We found that the microenvironmental niche plays a bigger
role in determining the growth and heterogeneity of the tumor when ∆death is not high. When ∆death is
sufficiently small, the microenvironmental niche influences which cells survive the longest, though all cells
will eventually die. Cells originally located near the low-drug/normoxic niche initially accumulate damage
at a much slower rate than their neighbors while still increasing their death threshold. The rest of the less
favorably placed population die out first as damage exceeds the death threshold, but the benefit of the low-
drug/normoxic niche enables the few remaining cells to survive longer and even experience a second short
period of growth before damage overwhelms them (Section 3.4.1).
For mid-range values of ∆death, we observed the case of almost successful treatment discussed in Sec-
tion 3.4.2. This behavior is driven by the microenvironmental niche. Cells initially placed near the low-
drug/normoxic niche are selected for, and the increase in ∆death lends them the time needed to reproduce
enough to move the tumor mass toward the hypoxic region. The result is a colony of a few surviving hypoxic
cells descended from the parent cells initially placed in the low drug niches.
When ∆death is at a higher value, the microenvironmental niche also determines which cells survive. In
this case, however, the surviving cells actually result in treatment failure. The tumor that eventually takes
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over tissue space lacks clonal diversity. The selective powers of the microenvironmental niche are highlighted
in Fig.1g. The first period of selection occurs after a clonally heterogeneous tumor starts to overtake tissue
space. Essentially all cells, with the exception of those in low-drug niches, accumulate high enough damage
levels to be killed by the drug (Fig.1g(iii)). The tumor temporarily repopulates some of space from these
low-drug regions, but again experiences a period of die-off when cells enter higher-drug regions. The cells
that survive this selection process are mostly found in a low-drug/hypoxic niche, and it is these cells that
eventually result in a clonally homogeneous tumor repopulating tissue space (Fig.1g(v,vi)).
For large values of ∆death, however, the role of the microenvironmental niche is reduced. The cancer
cells develop resistance to the drug very quickly for sufficiently large ∆death. As few clones die out, this
results in a monotonically growing tumor (Fig.5d) composed of clones from all over the tissue landscape,
similar to what is observed in the case of no treatment (Fig.1b).
In conclusion, the microenvironmental niche plays different roles for different values of ∆death, the rate
at which cells build up tolerance to the DNA damaging drug. When it is small, the microenvironment selects
which cells will survive the longest before ultimately dying. As ∆death increases to mid-range values, cells
located near the low-drug/normoxic niche are able to develop resistance and propagate, eventually leading
to the formation of a resistant tumor. For large values of ∆death, location becomes less important and cell
survival is guaranteed by the increase of the death threshold alone.
4. Discussion. In this paper we addressed the emergence of a resistant tumor when a DNA damaging
drug is continuously administered by an intravenous injection. We have developed a spatial agent-based
model that can examine tumor response to the drug in a heterogeneous microenvironment. This environ-
ment is comprised of non-uniformly spaced vasculature that results in an irregular gradient of oxygen and
drug. We specifically focused on the difference between pre-existing and acquired drug resistance. By using
identical initial microenvironmental conditions we were able to compare the dynamics and clonal evolution
of the developing tumor in these two cases. We have also conducted a theoretical analysis of the temporal
components of the model for both types of resistance.
The model produced several interesting results. In both cases considered, the pre-existing or acquired
drug resistance is initiated independently in individual cells (cellular level). However, during the course of
treatment three types of population behaviors (tissue level) are observed: 1) tumor eradication; 2) emergence
of a drug resistant tumor; and 3) a non-responsive tumor. In order to observe these three parameter regimes
in the case of pre-existing resistance, DNA damage repair must be included in the model (p > 0). Varying
the pre-existing resistance parameter (Thrmulti) without including DNA damage repair can only give rise to
the case of tumor eradication (Proposition 3.1.1). On the other hand, in the case of acquired resistance all
three parameter regimes are achievable without the inclusion of DNA damage repair. Final tumor behavior
in this case depends on the speed with which the cells build tolerance to DNA damage (∆death).
In particular, in the cases with pre-existing resistance, both the theoretical analysis and the agent-based
simulations produced the same conclusions: a) with a low DNA damage repair term, both the resistant and
sensitive clones died; b) with a medium DNA damage repair term, resistant clones survived but sensitive
clones died; and c) for high levels of the DNA damage repair term, all clones survived regardless of their
phenotype. The reason for this correlation between computational simulations and theoretical analysis is
that in the pre-existing resistance case, the spatial component has no significant effect on the long-term
outcome. Similarly, in the acquired resistance case: a) with a slow increase in the cell death threshold, all
of the cells eventually died out; b) with an intermediate increase in the death threshold, some of the clones
die but the tumor eventually develops resistance to the drug; and c) with a high increase in the cell death
threshold, all clones are able to survive resulting in treatment failure.
In the cases where a drug resistant tumor forms (Fig.1g,h), some common spatial dynamics are observed.
The cells located near vasculature are first affected by the drug and often die. The least affected are the cells
that occupy low drug/normoxia niches, and these cells are often able to repopulate the tumor. Final clonal
configurations can vary from mono-clonal (acquired case) to bi-clonal (pre-existing case), to multi-clonal
(acquired case). However, in the case of acquired resistance, we have also observed a case when only a
small number of cells remained quiescent in the hypoxic areas for a prolonged time. These cells have not
accumulated enough damage to die, and since they are located in the area of both low drug and oxygen,
they have time for DNA repair. Thus, the existence of microenvironmental niches of either low drug or low
oxygen concentrations are the driving forces in both transient and long-term tumor cell survival. Further, in
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the case of acquired resistance, the spatial location of certain clones makes them more fit than the other cells
and allows them to overtake the available space. In conclusion, when the cell has a pre-existing resistance
the genetic fitness advantage seems to be more important than any spatial fitness advantage, whereas the
spatial position of tumor clones plays a more important role when drug resistance is acquired.
When studying the case of acquired resistance we assumed that all cells react to drug exposure in
the same way and are thus all equally capable of acquiring resistance. This choice allowed us to focus
on how microenvironmental differences select which cells acquire resistance, but our model could also be
extended to take into account intrinsic cellular differences. In particular, it is possible that acquired drug
resistance occurs when only a single cell, rather than the whole population, possesses the ability to acquire
resistance. Investigating the interaction of cellular and microenvironmental differences is an interesting
problem, especially because our simulations show that varying how strongly cells respond to drug exposure
(∆death) can lead to clonally heterogeneous or homogenous tumors. Since we framed acquired resistance
broadly as a reaction of cells to increased and prolonged exposure to drug, it is possible to use this general
framework to account for a variety of the mechanisms of acquired resistance. For example, resistance may
be due to increased drug efflux pumps or a simple lack of any drug dosage effect. Both of these mechanisms
could be studied with our model by changing how we think about the damage level and death threshold.
The damage level is related to how much drug the cell has encountered, and the death threshold at its most
general level describes how the cell reacts to damage. Thus, it is possible that the cell reacts to damage less
(and hence has a higher death threshold) because of enhanced drug efflux pumps or a less effective drug.
Our model can also be extended to address other important aspects of tumor resistance. In this paper,
we limited our investigation to a continuously administered drug. In the future we will investigate different
drug scheduling schemes including typical clinical protocols, as well as metronomic and adaptive schedules.
Beyond the drug schedule, we can expand the model from considering DNA damaging drugs to considering
other drugs with different killing mechanisms, including anti-mitotic drugs or drugs activated in specific
microenvironmental conditions (low oxygen or high acidosis). This allow us to further extend our model to
study drug combinations. This is especially important, because in clinical practice, when the tumor cells
become resistant to a given drug, the treatment is often changed to another therapeutic agent. However, it
has been observed that resistance to one drug is accompanied by resistance to other drugs whose structures
and mechanisms of action may be completely different (multiple drug resistance). Thus, this poses interesting
questions for future research. If the hypothesis of a pre-existing population of resistant cells is true, what
mechanisms enable those cells to resist the drug action of the often multiple chemotherapeutic treatments
that may be given to a patient sequentially or in parallel? If the hypothesis of gradual emergence of drug
resistance is true, what factors contribute to the development of acquired drug resistance? The mathematical
framework developed here has the potential to address multiple aspects of drug resistance in solid tumors
and test methods for increasing efficacy of drug combinations.
Our model belongs to a category of spatial hybrid discrete-continuous models of anti-cancer drug resis-
tance. While mathematical modeling of tumor growth and therapy (mathematical oncology) dates back now
over half a century [21], the modeling of anti-cancer drug resistance have gained its momentum in the last
couple of years [22, 23, 24, 25]. However, most of the mathematical models to date addressed the problem of
drug resistance on a level of the whole cell population using a variety of mathematical approaches: stochastic
models [26], evolutionary dynamics [27, 28, 29, 30], game theory [31], Lamarckian induction [32], compart-
mental pharmacokinetic models [33], or continuous PDE models [34, 35]. Very few models of drug resistance
have, like ours, considered the significant role of spatial tumor structure and/or interactions between cells
and their microenvironment. Silva and Gatenby used an agent-based model of cells equipped with internal
metabolic machinery to investigate cell-cell and cell-microenvironment interactions during chemotherapy,
and strategies to prolong survival in the case of pre-existing resistance [36]. This work showed that ad-
ministration of the chemotherapy with the goal of stabilization of tumor size instead of eradication would
yield better results than use of maximum tolerated doses, thus preventing or at least delaying tumor relapse.
The authors demonstrated that fast growing sensitive cells can serve as a shield keeping the resistant cells
trapped inside the tumor. Lorz et al used a continuous model of anti-cancer therapy resistance under the
assumption that resistance is induced by adaptation to drug environmental pressures [37]. This has been
modeled using a concept of the expression level of a resistance gene influencing tumor cells birth/death rates,
effects of chemotherapies and mutations. The same group has also considered how the spatial structure plays
a role in resistance development under combined therapy protocols. By including spatial structure into the
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model, the authors were able to suggest that adaptation to local conditions (microenvironment) is directly
linked to resistance development [38]. Lavi et al used another continuous model of multi-drug resistance
with a variable cell resistance level that takes the form of a structure population model. This allowed the
authors to explore how cells evolve (and may be selected for) under stress imposed by cytotoxic drugs [39].
The same group has also investigated how trait selection may give rise to different types of resistance and
what implications this may have for tumor heterogeneity (at the level of mutations) [40]. A recent work of
Powathil et al, that uses the Cellular Potts framework has been employed to investigate how the cell-cycle
dynamics and oxygen concentration changes influence the development of resistance [41]. The authors sug-
gested that cell-cycle-mediated drug resistance emerges because the chemotherapeutic treatment gives rise
to a dominant, slow-cycling subpopulation of tumor cells, causing the drug failing to target all cancer cells.
Our model differs significantly from the models discussed above. We not only consider and compare two
types of resistance, but also identify two microenvironmental niches that have an impact on emergence of
resistant cells. While other hybrid models use similar approach to model tumor cell interactions with oxygen
and drugs, they treat tumor microenvironment as a homogeneous medium [36]. In contrast, our model
incorporates a more realistic configuration of tumor vasculature that produces gradients of metabolites that
are of irregular shapes and can change dynamically in time. Thus we can directly observe the emergence
of microenvironmental niches (Fig.1g(iii),(iv)) that protect cells from killing by drugs, and enable some of
them to develop resistance. We also investigated the interplay between tumor clonal development within
the spatially and temporally variable distributions of both drug and oxygen, that has not been addressed
by any of the previous hybrid models of drug resistance. The presented model is quite general and the
self-calibration methods have been used for it parameterization (see the Appendix).
Our model reproduces a broad range of tumor behaviors observed in clinical practice. However, our
chosen parameters have not been tuned to represent a particular drug and a particular tumor type. Therefore
the model constitutes a good starting point for more precise calibration to both tumor morphology and
drug pharmacokinetic properties. In particular, in the future we plan to use more realistic tumor tissue
morphologies based on patients’ histology samples. This will include both more realistic vasculature that
may vary between tumors of different origins, various stromal components such as stromal cells (fibroblasts
or adipocytes) and immune cells (macrophages, T cells, lymphocytes), extracellular matrix fibril structure,
and various distributions of metabolites (oxygen, glucose, acids, MMPs). In particular, the role of the tumor
microenvironment in the development of drug resistance is becoming a key consideration in the development
of novel chemotherapeutic agents. The interactions between tumor cells and their surrounding physical
environment can influence cell signaling, survival, proliferative capacities and cell sensitivity to drugs. Thus
extracellular factors including tumor hypoxia and acidity, as well as tumor cell density and the extracellular
matrix composition that limit drug penetration, should be investigated in a quantitative way via combination
of laboratory experimentaion and mathematical modeling.
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APPENDIX
Before testing various mechanism of tumor resistance, our model has been calibrated to 1) achieve a
stable gradient of oxygen when no cancer cells are present, as would be the case in healthy tissue; 2) generate
a tumor cluster that completely fills the available space when no drug is applied as would take place in non-
treated tumors; this will result in another stable gradient of oxygen with hypoxic areas located far from the
vasculature; and 3) completely eliminate the tumor when the cells do not acquire resistance. These three
self-calibration steps are discussed in this section.
First, the influence of oxygen and drug are normalized so that Sξ=Sγ=1. Then we determine the
oxygen diffusion coefficient Dξ and oxygen boundary conditions that lead to a (numerically) stable gradient
of oxygen when no cancer cells are present; that is with no cellular uptake. Several boundary conditions were
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Fig. 9. Oxygen distribution and its stabilization error curves. (a,b) Numerically stable gradients of oxygen in a
domain with no cancer cells (a), and in a domain where non-treated cancer cells uptake oxygen (b). The grey-scale
contours indicate oxygen distribution levels. (c,d) Relative 2-norm error of oxygen changes ‖η(x, t+ ∆t)− η(x, t)‖2
calculated for 25000 iterations showing its numerical stability for cases (a) and (b), respectively.
considered, however, the best results in terms of irregular gradient stabilization and the extent of hypoxic
areas were achieved for the sink-like conditions with $=0.45 (see Section 2.1). The resulting stable oxygen
gradient is shown in Fig. 9a and the relative 2-norm error between two oxygen concentrations generated in
two consecutive time steps is shown in Fig. 9c. The obtained oxygen gradient served as an initial condition
for the reaction-diffusion equation for oxygen.
Next, a tumor cell oxygen uptake rate pξ and a hypoxia threshold Thrhypo were selected to allow
for tumor growth with a small subpopulation of hypoxic cells, and for generation of a (numerically) stable
gradient of oxygen when the tumor reaches its stable configuration. This population of tumor cells, including
the hypoxic cell fraction and tumor clonal composition, serves as a control case (with no treatment) shown
in Fig. 1b. For the stable tumor population the (numerically) stable oxygen gradient is shown in Fig. 9b,
and the relative 2-norm error of the oxygen changes over 25, 000 iterations is shown in Fig. 9d.
Finally, the drug diffusion coefficient Dγ , drug uptake rate pγ , and death threshold Thrdeath were
determined so that the cluster of tumor cells with no resistance is eradicated. This ensures that for the
chosen drug parameters, the drug is effective when there are no resistant tumor cells. This case is discussed
in Section 3.1. All parameters determined by the procedure described here are listed in Table 2.
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